IS CONGENITAL ADRENAL HYPERPLASIA DUE TO 21- HYDROXYLASE DEFICIENCY DECEPTIVE DISEASE? MANAGEMENT AND DIFFERENTIATION OF SYNDROME IN ADULTS

  • Anna Nowak Medical University of Warsaw, Poland
Keywords: congenital adrenal hyperplasia, 21- hydroxylase, glucocorticosteroids

Abstract

Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase defi ciency is one of the most common autosomal recessive hereditary diseases. The lack of cortisol synthesis leads to excessive stimulation of the adrenal glands by adrenocorticotropic hormone (ACTH). Moreover the impairment of cortisol synthesis results in adrenal hyperplasia and excessive androgen synthesis. Congenital adrenal hyperplasia is characterised by a considerable correlation between the genotype and the phenotype with the type of CYP21A2 gene mutation affecting the severity of 21-hydroxylase defi ciency. The clinical manifestations of congenital adrenal hyperplasia in adults result from adrenocortical insuffi ciency, hyperandrogenism, and the adverse effects of glucocorticosteroids, which are used for the treatment of the syndrome. Non-classic congenital adrenal hyperplasia may sometimes be asymptomatic. Patients with classic congenital adrenal experience a wide variety of symptoms, including obesity, hyperinsulinaemia, insulin resistance, and hyperleptinaemia. These abnormalities promote the development of metabolic syndrome and its sequelae, including endothelial dysfunction, and cardiovascular disease. The symptoms are more often seen in patients suffering from congenital adrenal hyperplasia syndrome than in the general population. Long-term glucocorticosteroid treatment is also a known risk factor for many diseases, for instance osteoporosis. Patients with congenital adrenal hyperplasia require constant monitoring of biochemical parameters (17a-hydroxyprogesterone [17-OHP] and androstenedione), clinical parameters (Body Mass Index, waist circumference, blood pressure, glucose, and lipids), and bone mineral density by densitometry. Appropriate treatment of congenital adrenal hyperplasia is extremely important. The principal goal of treatment in adults with CAH is to improve quality of life, ensure that they remain fertile, reduce the manifestations of hyperandrogenisation in females. Furthermore it is key to reduce the adverse effects of medicaments used for therapy of the CAH syndrome. Patients with classic congenital adrenal hyperplasia require treatment with glucocorticosteroids and, in cases of salt wasting, also with a mineralocorticosteroid. Radical measures, such as bilateral adrenalectomy, are very rarely needed. Asymptomatic patients with non-classic congenital adrenal hyperplasia require monitoring; treatment is not always necessary. Medical care for patients suffering from congenital adrenal hyperplasia should be provided by reference centres, as the management of such patients requires collaboration between an endocrinologist, diabetologist, gynaecologist, andrologist, urologist, and psychologist.

Downloads

Download data is not yet available.

References

Ambroziak U, Bednarczuk T, Ginalska-Malinowska M, Małunowicz EM, Grzechocińska B, Kamiński P, Bablok L, Przedlacki J, Bar-Andziak Congenital adrenal hyperplasia due to 21-hydroxylase deficiency- management in adults. Endokrynologia Polska. 2010;61(1):142-5.

Deborah Merke; Genetics and clinical presentation of classic congenital due to 21-hydroxylase deficiency White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocrine reviews. 2000 Jun 1;21(3):245-91.

Romer Wrodzony przerost kory nadnerczy. In: Syrenicz A (ed.). [In Polish]

Endokrynologia w codziennej praktyce lekarskiej. Wydawnictwo Pomorskiej Akademii Medycznej w Szczecinie 2009:519–556. [In Polish]

Pang S, Clark A, Neto EC, Giugliani R, Dean H, Winter J, Dhondt JL, Farriaux JP, Graters A, Cacciari E, Balsamo A. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: newborn screening and its relationship to the diagnosis and treatment of the Screening. 1993 Apr 1;2(2-3):105-39.

Speiser PW, Dupont J, Zhu D, Serrat J, Buegeleisen M, Tusie-Luna MT, Lesser M, New MI, White PC. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase Journal of Clinical Investigation. 1992 Aug;90(2):584.

https://doi.org/10.1172/JCI115897

New MI. Nonclassical 21-hydroxylase deficiency. The Journal of Clinical Endocrinology & Metabolism. 2006 Nov;91(11):4205-14.

https://doi.org/10.1210/jc.2006-1645

Ambroziak U. Przełom nadnerczowy. In: Hryniewiecki T (ed.). Stany nagłe. Medical Tribune Polska, Warszawa 2009:198–200. [In Polish]

Anderson JR, Ross AM. Ectopic adrenal tissue in adults. Postgraduate medical journal. 1980 Nov;56(661):806.

https://doi.org/10.1136/pgmj.56.661.806

Azziz R, Zacur HA. 21-Hydroxylase deficiency in female hyperandrogenism: screening and diagnosis. The Journal of Clinical Endocrinology & Metabolism. 1989 Sep 1;69(3):577-84.

https://doi.org/10.1210/jcem-69-3-577

Baron JJ, Baron J. Differential diagnosis of hirsutism in girls between 15-19 years old. Ginekologia pol- ska. 1993 May;64(5):267-9.

Moran C, Azziz R, Carmina E, Dewailly D, Fruzzetti F, Iba-ez L, Knochenhauer ES, Marcondes JA, Mendonca BB, Pignatelli D, Pugeat M. 21-Hydroxylase–deficient nonclassic adrenal hyperplasia is a progressive disorder: A multicenter American journal of obstetrics and gynecology. 2000 Dec 31;183(6):1468-74.

https://doi.org/10.1067/mob.2000.108020

Jaresch SU, Kornely EL, Kley HK, Schlaghecke Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia. The Journal of Clinical Endocrinology & Metabolism. 1992 Mar 1;74(3):685-9.

Bauman A, Bauman CG. Virilizing adrenocortical carcinoma: Development in a patient with salt-losing congenital adrenal hyperplasia. 1982 Dec 17;248(23):3140-1.

Mora S, Saggion F, Russo G, Weber G, Bellini A, Prinster C, Chiumello Bone density in young patients with congenital adrenal hyperplasia. Bone. 1996 Apr 1;18(4):337-40.

https://doi.org/10.1016/8756-3282(96)00003-8

Jääskeläinen J, Voutilainen R. Bone mineral density in relation to glucocorticoid substitution therapy in adult patients with 21-hydroxylase deficiency. Clinical endocrinology. 1996 Dec 1;45(6):707-13.

https://doi.org/10.1046/j.1365-2265.1996.8620871.x

Ambroziak U, Bednarczuk T, Przedlacki J et Bone metabolism and elements of metabolic syndrome in young adults with CAH in chronic glucocorticoid treatment. ENDO, Washington. 2009.

Charmandari E, Brook CG, Hindmarsh Classic congenital adrenal hyperplasia and puberty. European journal of endocrinology. 2004 Nov 1;151(Suppl 3):U77-82.

https://doi.org/10.1530/eje.0.151U077

Malouf MA, Migeon CJ, Carson KA, Petrucci L, Wisniewski Cognitive outcome in adult women affected by congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hormone Research in Paediatrics. 2006;65(3):142-50.

https://doi.org/10.1159/000091793

Małunowicz EM. Nieklasyczna postać wrodzonego przerostu kory nadnerczy z powodu niedoboru 21-hydroksylazy (nk-wpn) u dziewczynek i kobiet z objawami androgenizacji. Endokrynologia Ped 2008;7:9–18. [In Polish]

Miller The adrenal cortex. In: Rudolph AM, Hoffman JIE (ed.). Pediatrics. Appleton & Lange, Norwalk 1991:1584–1614.


Abstract views: 85
PDF Downloads: 89 PDF Downloads: 0
Published
2017-12-20
How to Cite
1.
Nowak A. IS CONGENITAL ADRENAL HYPERPLASIA DUE TO 21- HYDROXYLASE DEFICIENCY DECEPTIVE DISEASE? MANAGEMENT AND DIFFERENTIATION OF SYNDROME IN ADULTS. Proc Shevchenko Sci Soc Med Sci [Internet]. 2017Dec.20 [cited 2022Jul.2];50(2):48-4. Available from: https://mspsss.org.ua/index.php/journal/article/view/105